Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Net Income | -- | -- | 33.57% | -20.73% | |
| Total Depreciation and Amortization | -- | -- | -- | 227.62% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -- | -- | -237.82% | 146.96% | |
| Change in Net Operating Assets | -- | -- | -281.33% | 19.35% | |
| Cash from Operations | -- | -- | 9.07% | -8.18% | |
| Capital Expenditure | -- | -- | 72.85% | 55.81% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | 196.67% | 112.84% | |
| Cash from Investing | -- | -- | 75.64% | 64.59% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -10.38% | -182.32% | |
| Issuance of Common Stock | -- | -- | -99.91% | -14.17% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | 90.56% | 41.97% | |
| Cash from Financing | -- | -- | -85.33% | 16.11% | |
| Foreign Exchange rate Adjustments | -- | -- | -544.29% | -865.13% | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -- | -- | -154.36% | 45.26% | |